| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8220969 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 7 Pages |
Abstract
This review demonstrates better outcomes for indolent histology compared with DLBCL-leg, validating the prognostic utility of the WHO-EORTC classification. In the indolent group, RT was associated with 98% local control. DLBCL-leg is a more aggressive disease; the excellent results in the rituximab group suggest it has an important role in management.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Sarah N. MD, Elaine S. MD, King MBBS, Cheryl Alexander, Randy D. MD, Joseph M. MD,